Marshall Wace

Marshall Wace’s Evommune Inc EVMN Stock Holding History

Marshall Wace’s Portfolio EVMN Stock Details EVMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.2M	Sell	879,728 -108,472	-11%	-$2.45M	0.02%	700
2025 Q4	$16.9M	Buy	+988,200	New	+$18.6M	0.02%	686

Other funds holding EVMN

EQT Fund Management Luxembourg $1.02B AUM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Andera Partners Paris $206M AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

JP Morgan Chase

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Marshall Wace's EVMN Position: Q1 2026 in Review

Marshall Wace reduced its Evommune Inc (EVMN) stake by 11% in Q1 2026, selling an estimated $2.45M and leaving 879,728 shares worth $20.2M. The position accounts for 0.02% of the portfolio, ranked #700.

Marshall Wace first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

Marshall Wace held 879,728 shares of Evommune Inc worth $20.2M as of Q1 2026.
Marshall Wace sold 108,472 Evommune Inc shares in Q1 2026, an estimated $2.45M.
Evommune Inc made up 0.02% of Marshall Wace's portfolio in Q1 2026, its #700 holding.
Marshall Wace first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.